Successful Treatment of Pityriasis Rubra Pilaris with Upadacitinib: Report of Two Cases
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0149Keywords:
pityriasis rubra pilaris, janus kinase inhibitor, JAK-STATDownloads
References
Feldmeyer L, Mylonas A, Demaria O, Mennella A, Yawalkar N, Laffitte E, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol 2017; 153: 304–308. DOI: https://doi.org/10.1001/jamadermatol.2016.5384
Boudreaux BW, Pincelli TP, Bhullar PK, Patel MH, Brumfiel CM, Li X, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol 2022; 187: 650–658. DOI: https://doi.org/10.1111/bjd.21708
Haynes D, Strunck JL, Topham CA, Ortega-Loayza AG, Kent G, Cassidy PB, et al. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial. JAMA Dermatol 2020; 156: 668–675. DOI: https://doi.org/10.1001/jamadermatol.2020.0932
Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol 2018; 79: 353–359. DOI: https://doi.org/10.1016/j.jaad.2018.03.036
Li Y, Chen Z, He M, Tan X, Nie S, Zeng Y, et al. Successful treatment of erythrodermic pityriasis rubra pilaris with upadacitinib. J Eur Acad Dermatol Venereol 2024; 38: e593–e595. DOI: https://doi.org/10.1111/jdv.19762
Xiaoyuan P, Lin S, Xinyu Z, Qianya S, Mei C, Fei W, et al. Successful treatment of generalized pustular psoriasis coexisting with pityriasis rubra pilaris with upadacitinib. Indian J Pediatr 2024; 91: 1296. DOI: https://doi.org/10.1007/s12098-024-05214-x
Song EJ, Al-Saedy MA, Bouché N. Refractory pityriasis rubra pilaris treated with upadacitinib. JAAD Case Rep 2023; 35: 112–114. DOI: https://doi.org/10.1016/j.jdcr.2023.03.004
Zhang X, Wei K, Song H, Chen X, Yang J, Zhao J, et al. Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—a systematic review. Front Med 2025; 12: 1544197. DOI: https://doi.org/10.3389/fmed.2025.1544197
Strunck JL, Cutler B, Rajpal B, Kent G, Haynes D, Topham CA, et al. Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels. J Invest Dermatol 2022; 142: 235–239. DOI: https://doi.org/10.1016/j.jid.2021.06.009
Virtanen A, Spinelli FR, Telliez JB, O’Shea JJ, Silvennoinen O, Gadina M. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol 2024; 20: 649–665. DOI: https://doi.org/10.1038/s41584-024-01153-1
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
